Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18856572 | 0.77 | ESR1 (0.43) | MEN1KMT2AMAPTHTT | |
| SCHEMBL799603 | 0.75 | MAPT (0.46) | SMN1; SMN2MEN1KMT2AMAPTHTT | |
| SCHEMBL799579 | 0.71 | HPGD (0.49) | SMN1; SMN2MEN1KMT2AMAPTHTT | |
| SCHEMBL799954 | 0.69 | ALDH1A1 (0.44) | SMN1; SMN2MEN1KMT2AMAPTHTT | |
| SCHEMBL10078955 | 0.69 | AHR (0.45) | AHRSMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL9980406 | 0.68 | SOS1 (0.54) | SMN1; SMN2MEN1KMT2AMAPTHTT | |
| SCHEMBL13167790 | 0.64 | RAPGEF4 (0.41) | AHRRAPGEF4HTT | |
| SCHEMBL14112775 | 0.64 | PDE4A (0.51) | SMN1; SMN2MEN1KMT2AMAPTHTT | |
| SCHEMBL47577 | 0.63 | MITF (0.36) | MEN1KMT2A | |
| SCHEMBL13949442 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170136007-A1 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | THE FEINSTEIN INST MEDICAL RES (US) | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170136007-A1 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | CHRNA7, CHRNA5, CHRM5 | AHR 1105/4885SMN1; SMN2 468/4885RAPGEF4 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.